Cybernet Data Systems Inc.
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, announced its financial results for the second fiscal quarter ended September 30, 2020. The company achieved several significant operational and commercial planning milestones in preparation for the U.S. Food and Drug Administration&
Cybernet Data Systems Inc.
Advanced Disposal Services, Inc., a Delaware corporation, has entered into Amendment No. 1 to the Securities and Asset Purchase Agreement with GFL Holdco (US), LLC, a Delaware limited liability company, and other parties related to the previously announced merger between Advanced Disposal and Waste Management, Inc. The amendment modifies the
Cybernet Data Systems Inc.
Sunesis Pharmaceuticals, a biopharmaceutical company, has paid off its outstanding debt and reported preliminary financial figures for the second quarter of 2020. The company has executed a payoff letter to repay approximately $5.7 million to Silicon Valley Bank, terminating all commitments and obligations under its term loan agreement. As
Information technology services industry
T-Mobile, Sprint, and DISH Network Corporation have agreed to amend the Asset Purchase Agreement, signed on July 26, 2019, to proceed with the acquisition of Sprint's prepaid wireless business. The DOJ has consented to the closing of the Prepaid Business Sale on July 1, 2020, subject to the
Information technology services industry
DISH Network Corporation and T-Mobile US, Inc. have entered into the First Amendment to the Asset Purchase Agreement, amending the original agreement to close the transaction on July 1, 2020. The amendment extends the termination date of the Asset Purchase Agreement to July 1, 2020, subject to the terms and
Information technology services industry
Simon Property Group, Inc. ("Simon") has terminated its February 9, 2020 merger agreement with Taubman Centers, Inc. ("Taubman") due to the occurrence of a material adverse effect in respect of Taubman and breaches of multiple provisions of the merger agreement. The termination is based on two
Information technology services industry
Taubman Centers, Inc. (NYSE: TCO) has confirmed receipt of a notice from Simon Property Group, Inc. (NYSE: SPG) purporting to terminate the previously announced Agreement and Plan of Merger. However, Taubman believes that Simon's action is invalid and without merit, and that Simon continues to be bound to
Information technology services industry
Evofem Biosciences, a commercial-stage biopharmaceutical company, has announced the FDA approval of Phexxi, a non-hormonal, on-demand vaginal pH regulator contraceptive. Phexxi is the first of its kind, designed to maintain vaginal pH within the normal range of 3.5 to 4.5, creating an acidic environment that is inhospitable to
Information technology services industry
Kimco Realty Corp., one of North America's largest publicly traded owners and operators of open-air, grocery-anchored shopping centers and mixed-use assets, announced that it will partially monetize its investment in Albertsons Companies, Inc. as part of Albertsons' $1.75 billion sale of convertible preferred stock. The company
Cybernet Data Systems Inc.
Chesapeake Utilities Corporation has entered into a Loan Agreement with Royal Bank of Canada, providing for a revolving line of credit of up to $20 million. The agreement, which includes a revolving line of credit and specific business and financial covenants, is intended to provide incremental liquidity in the current
Cybernet Data Systems Inc.
First Interstate BancSystem, a financial and bank holding company, has announced plans to offer subordinated notes due 2030, subject to market and other conditions. The company intends to use the net proceeds from the offering for general corporate purposes. Piper Sandler & Co. is acting as the sole book-running manager
Cybernet Data Systems Inc.
Amicus Therapeutics is a patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The company's cornerstone product, Galafold(R) (also referred to as "migalastat"), has achieved widespread global approval as the first and only approved oral precision medicine for people living
